Subscribe: Market Wire - Pharmaceuticals and Biotech: Biotech
Added By: Feedage Forager Feedage Grade B rated
Language: English
announced  announces  company  jul  july  marketwired jul  marketwired july  marketwired  medical  new  today announced  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Biotech

Marketwired - Biotech

Marketwired - Biotech

Last Build Date: Wed, 26 Jul 2017 09:02:26 EDT

Copyright: Copyright: (C) Marketwired

NetworkNewsWire Announces Publication on Leading Innovators Working to Unlock a Treatment for Alzheimer's

Wed, 26 Jul 2017 08:30:00 EDT

NEW YORK, NY--(Marketwired - Jul 26, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring India Globalization Capital, Inc. (NYSE MKT: IGC), a client of NNW positioned as a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.

BioVie Files Patent Application in Japan for BIV201 for the Treatment of Ascites Due to Liver Cirrhosis

Wed, 26 Jul 2017 08:00:00 EDT

BEVERLY, MA--(Marketwired - July 26, 2017) - BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, announced today the filing of an application in Japan for patent coverage of the Company's new drug candidate BIV201 for the treatment of ascites in patients with advanced liver cirrhosis. This follows the recent issuance of US Patent No. 9,655,945 for the use of BIV201 to treat this medical condition. The Company is pursuing an approach known as the "patent prosecution highway" in order to seek an expedited patent approval in Japan, which may take less than one year.

Medigus Broadens Availability of MUSE(TM) Through Distribution Agreement With ADMEDICS AG in Switzerland and Liechtenstein

Wed, 26 Jul 2017 07:00:00 EDT

New agreement expands accessibility of MUSE(TM) in new markets

Top Pharma Companies Now Include Communicating HEOR Data as a Part of Their Medical Affairs Strategy

Tue, 25 Jul 2017 17:42:00 EDT

RESEARCH TRIANGLE PARK, NC--(Marketwired - July 25, 2017) - New analysis of Top 10, Top 50 and small medical device companies revealed that health economics and outcomes research (HEOR) data is increasingly becoming a part of surveyed medical affairs teams' strategies, according to pharmaceutical business intelligence firm Cutting Edge Information.

Tetra Bio-Pharma Announces Stock Option Grant to CEO

Tue, 25 Jul 2017 17:00:00 EDT

OTTAWA, ONTARIO--(Marketwired - July 25, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announces that it has made a grant of stock options under its stock option plan to the newly appointed Chief Executive Officer, Bernard Fortier to acquire a total of 400,000 common shares of the Company. All of the options are exercisable at a price of $0.80 per share. All of the options will vest immediately of the date of grant. The options have a term of 4 years and are subject in all respects to the terms of Tetra's stock option plan.

Helix BioPharma Corp. Initiates Enrollment in the Third Dosing Cohort of U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47

Tue, 25 Jul 2017 16:30:00 EDT

TORONTO, ONTARIO--(Marketwired - July 25, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening in the third dosing cohort of its ongoing U.S. study of L-DOS47 in combination treatment with pemetrexed/carboplatin ("LDOS001").

Tauriga Sciences, Inc. and Ice + Jam LLC Prepare for Autumn 2017 Commercial Product Launch with Commencement of Laboratory Work to Reformulate Cupuacu Butter Lip Balm Product Texture

Tue, 25 Jul 2017 11:00:00 EDT

NEW YORK, NY--(Marketwired - Jul 25, 2017) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), engaged in the building of life sciences businesses and technologies, today announced that, in cooperation with its licensor Ice + Jam LLC ("Ice + Jam"), it is working with New Jersey based Cosmetics R & D Laboratory, Ariel Laboratories ("Ariel Labs"), to reformulate its proprietary Cupuacu Lip Balm Product (Branded as: "HerMan"). In preparation for its anticipated Autumn 2017 commercial product launch, Tauriga has prioritized this laboratory work aimed at improving the texture and viscosity of the underlying Cupuacu Butter lip treatment. As previously disclosed on June 16, 2017, Tauriga and Ice + Jam have already incorporated the new and improved label design and graphics for the packaging of the HerMan product. The Company is hopeful that it can produce samples of the Final product within the next 6-8 weeks and then obtain some feedback from potential retailers and customers.

Neptune publiera ses résultats du premier trimestre pour la période de trois mois se terminant le 30 juin 2017

Tue, 25 Jul 2017 10:31:36 EDT

LAVAL, QUÉBEC--(Marketwired - 25 juillet 2017) - Neptune Technologies & Bioressources inc. (NASDAQ:NEPT)(TSX:NEPT) (« Neptune » ou « la Société »), annonce qu'elle tiendra une conférence téléphonique le 15 août 2017 à 8h00, heure normale de l'est, afin de commenter les résultats financiers du premier trimestre pour la période de trois mois se terminant le 30 juin 2017.

Neptune to Hold Conference Call to Discuss First Quarter Results for the Three Months Period Ended June 30, 2017

Tue, 25 Jul 2017 10:30:21 EDT

LAVAL, QUÉBEC--(Marketwired - July 25, 2017) - Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ:NEPT)(TSX:NEPT), announces that it will be holding a conference call on August 15, 2017 at 8:00 AM (EST) to discuss its first quarter results for the three months period ended June 30, 2017.

Tauriga Sciences Inc. Confirms Trial Date of November 14, 2017 and that its Motion for Jury Trial has been Granted by Presiding Judge Peter G. Sheridan -- Federal District Court New Jersey (Courthouse Location: Trenton, New Jersey)

Tue, 25 Jul 2017 09:00:00 EDT

NEW YORK, NY--(Marketwired - Jul 25, 2017) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), engaged in the building of life sciences businesses and technologies, today announced that its Motion for Jury Trial has been Granted by the presiding judge Peter G. Sheridan ("the Judge") in its ongoing litigation against its predecessor audit firm, Cowan Gunteski & Co. P.A. ("Cowan Gunteski"). Additionally, as part of this ruling, the Judge confirmed a Trial Date of November 14, 2017 at 10:00am EST -- Federal District Court New Jersey (Courthouse location: Trenton, New Jersey).

Utah Medical Products, Inc. Reports Financial Performance for Second Quarter 2017

Tue, 25 Jul 2017 09:00:00 EDT

SALT LAKE CITY, UT--(Marketwired - Jul 25, 2017) - In the second calendar quarter (2Q) and first half (1H) of 2017, Utah Medical Products, Inc. (NASDAQ: UTMD) achieved results which suggest the Company may significantly exceed previously announced goals for 2017.

CV Sciences, Inc. Hosts Lunch Seminar at National University of Natural Medicine 2017 Medical Cannabis Conference

Tue, 25 Jul 2017 08:45:00 EDT

Company Enters its Second Year Sponsoring Continuing Education for University Students, Alumni, and Local Practitioners Interested in Learning More about Cannabis-Related Research and Methodologies

FDA Allows Q-Cells(R) for First-In-Human Transverse Myelitis Trial

Tue, 25 Jul 2017 08:00:00 EDT

Phase 1/2a Trial Will Set the Stage for Applications in Multiple Sclerosis, Stroke and Spinal Cord Injury

AntriaBio Announces First Patient Dosed in Phase 1 Clinical Study of AB101

Tue, 25 Jul 2017 08:00:00 EDT

LOUISVILLE, CO--(Marketwired - July 25, 2017) - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with diabetes and metabolic diseases, announced today the dosing of the first patient in a Phase 1 first-in-human clinical trial of its lead product candidate, AB101.

Livewire Ergogenics, Inc. Announces Strategic Development Agreements and Appointments to Advisory Board

Tue, 25 Jul 2017 08:00:00 EDT

ANAHEIM, CA--(Marketwired - Jul 25, 2017) - LiveWire Ergogenics, Inc. (OTC PINK: LVVV), a company focused on research partnerships, product development and commercialization of cannabinoid-based products, today announced it has entered into development agreements with seasoned horticulturists Kyle McKay and Jason Olson. The company also announced their appointments to the newly formed "7xPure" Advisory and Compliance Board.

Moleculin's New Drug for the Treatment of Glioblastoma Nears Clinical Trials at MD Anderson Cancer Center

Tue, 25 Jul 2017 07:30:00 EDT

HOUSTON, TX--(Marketwired - July 25, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has agreed to provide support to help accelerate the start of a physician-sponsored Investigational New Drug (IND) application to study the Company's drug candidate WP1066 for the treatment of adult glioblastoma (brain tumors).

MCIG Inc. Aggressively Seeks Acquisition of Medical and Recreational Marijuana License

Tue, 25 Jul 2017 07:00:00 EDT

HENDERSON, NV--(Marketwired - Jul 25, 2017) - mCig, Inc. (OTCQB: MCIG), a diversified company servicing the legal cannabis markets with innovative products, technologies, and services. mCig, Inc. is in a process of implementing a strategic plan that will help the company to accelerate its growth by expanding its reach in the cannabis market.

Top Pharma Companies Nurture Relationships with Payers Before, During and After Launch to Ensure and Retain Market Access

Mon, 24 Jul 2017 18:54:00 EDT

RESEARCH TRIANGLE PARK, NC--(Marketwired - July 24, 2017) - Payer relationship management accounts for an average of 26% of surveyed global pharmaceutical and medical device companies' total market access budget, according to a recent study by business intelligence provider Cutting Edge Information.

Kane Biotech Announces Removal of All Debt from its Balance Sheet and Grant of Options

Mon, 24 Jul 2017 18:00:00 EDT

WINNIPEG, MANITOBA--(Marketwired - July 24, 2017) - Kane Biotech Inc. (TSX VENTURE:KNE) (the "Company" or "Kane Biotech") today announced it has paid out all its outstanding debt. This includes its $500,000 convertible note and $400,000 bridge loan.

Arch Biopartners Retains Market Maker and Arranges Non Brokered Private Placement Financing

Mon, 24 Jul 2017 16:00:00 EDT

TORONTO, ONTARIO--(Marketwired - July 24, 2017) - Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF) announced today it has retained Mackie Research Capital Corporation ("Mackie Research") to provide market-making services to the Company in compliance with, and subject to, the policies, guidelines and approval of the TSX Venture Exchange and other applicable legislation.

REMSleep Holdings Inc. Announces the DeltaWave and its Patent Application -- A New Revolutionary CPAP Nasal Interface Device Designed to Improve Treatment for Sleep Apnea Patients

Mon, 24 Jul 2017 12:21:24 EDT

DES MOINES, IA--(Marketwired - Jul 24, 2017) - REMSleep Holdings, Inc. (OTC PINK: RMSL) (OTC PINK: RMSLD) is pleased to announce that it has filed a non-provisional patent with the US Patent and Trademark Office (Patent number 15/595,990 filed on March 16, 2017). The patent is titled "New Generation Sleep Apnea Device" and will ultimately be marketed under the product name "DeltaWave."

Dewmar International BMC, Inc. (DEWM) Files Paperwork with the United States Patent and Trademark Office to Secure Intellectual Property Related to Cannabinoids and Parkinson's Disease

Mon, 24 Jul 2017 11:49:29 EDT

New provisional patent will advance Dewmar's intellectual property assets related to Cannabinoids and is a follow up to last week's USPTO filing for lung cancer

The Alliance for Regenerative Medicine Announces Second Reimbursement and Market Access-Focused White Paper in Three-Part Series Published in In Vivo

Mon, 24 Jul 2017 10:35:59 EDT

WASHINGTON, DC--(Marketwired - Jul 24, 2017) - The Alliance for Regenerative Medicine (ARM) today announced the publication of its reimbursement and market-access focused white paper, "New Payment and Financing Models for Curative Regenerative Medicines," available online today in In Vivo.

SpeeDx Eyes Clear Path toward Marketing Antibiotic Resistance and Detection Tests in US Market

Mon, 24 Jul 2017 09:35:25 EDT

On-track for De Novo submission after successful meeting with the FDA

GeoVax Joins with Scripps Research Institute and Institute of Human Virology at University of Maryland School of Medicine to Develop Lassa Fever Vaccine

Mon, 24 Jul 2017 09:00:00 EDT

ATLANTA, GA--(Marketwired - Jul 24, 2017) -  GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is collaborating with The Scripps Research Institute (TSRI) in La Jolla, CA, and the Institute of Human Virology (IHV) at the University of Maryland Medical School in Baltimore, MD, for advanced development of a preventive vaccine against Lassa hemorrhagic fever virus (LASV).

AXIM Biotech: Cannabinoid Potential Worth the Complexity --

Mon, 24 Jul 2017 09:00:00 EDT

REDONDO BEACH, CA--(Marketwired - Jul 24, 2017) -, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering AXIM® Biotechnologies Inc. (OTCQB: AXIM) and its approach to developing cannabinoid-based therapeutics. Medical marijuana legalization may be sweeping the nation, but the term is a bit of a misnomer when it comes to actual medical evidence. After all, medical cannabis hasn't been registered as a medicine in any country and only a handful of cannabinoid medicines have reached the market. The upshot is that many companies are working on developing cannabinoid-based therapeutics that appear very promising in early clinical trials.

Microbix Announces Leadership Transition

Mon, 24 Jul 2017 08:59:04 EDT

Cameron Groome Appointed CEO, Vaughn Embro-Pantalony Retiring

Easton Pharmaceuticals Provides Shareholder Update On Acquisitions, Its Recent MMJ Initiative And Progress On Its Woman's Diagnostics and Treatment Segment

Mon, 24 Jul 2017 08:42:30 EDT

TORONTO, ON--(Marketwired - Jul 24, 2017) -  Easton Pharmaceuticals Inc. (OTC PINK: EAPH) provides shareholder update on new and existing acquisitions including its medical marijuana venture and progress on its woman's diagnostics and treatment segment products.

Cancer Immunotherapy Company Vaxil Appoints Dr. Terry Plasse as Chief Medical Officer

Mon, 24 Jul 2017 08:30:00 EDT

TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - July 24, 2017) - VAXIL BIO LTD. (TSX VENTURE: VXL), an Israeli-Canadian biotech developing innovative immunotherapy treatments for cancer, is pleased to announce the appointment of Dr. Terry Plasse as its Chief Medical Officer, responsible for the Company's clinical program surrounding its drug candidate, ImMucinT. Dr. Plasse brings 30 years of clinical development experience, including advancing products from IND through to commercially marketed treatments for several big-pharma companies.

BriaCell Expands Targeted Pipeline via Acquisition of Sapientia Pharmaceuticals

Mon, 24 Jul 2017 08:30:00 EDT

BERKELEY, CA and VANCOUVER, BC--(Marketwired - July 24, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to announce that it has entered into a definitive share exchange agreement (the "Share Exchange Agreement") with its wholly-owned subsidiary, BriaCell Therapeutics Corp. ("BriaCell USA"), a Delaware corporation, Sapientia Pharmaceuticals, Inc. ("Sapientia") and all the shareholders of Sapientia (the "Sapientia Shareholders"). Sapientia, a biotechnology company based in Havertown, PA, that is developing novel targeted therapeutics for multiple indications including several cancers and fibrotic diseases.

Rennova Health Announces the Opening of Big South Fork Medical Center Is on Track for August 8 Following CMS Regional Office Licensure Approval

Mon, 24 Jul 2017 08:30:00 EDT

WEST PALM BEACH, FL--(Marketwired - July 24, 2017) - Rennova Health, Inc. (NASDAQ: RNVA), (NASDAQ: RNVAZ) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, announces the Life Safety and Licensure Survey conducted by the Tennessee Department of Health East Regional Office has concluded its inspection of Rennova's subsidiary Big South Fork Medical Center (legal name: Scott Community Hospital, Inc.), thereby approving the opening of Big South Fork Medical Center as planned for August 8, 2017.

Tetra Bio-Pharma Accelerates Growth Strategy with Appointment of Bernard Fortier as CEO

Mon, 24 Jul 2017 08:30:00 EDT

OTTAWA, ONTARIO--(Marketwired - July 24, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) today announced that it has strengthened its management team with the appointment of Bernard Fortier to the position of Chief Executive Officer, effective today, July 24, 2017. Mr. Andre Rancourt, previous interim CEO will take the position as Chairman of the Board of Directors. Mr. Andre Audet will step down as Chairman of the Board of Directors but will continue to serve as a Board member.

ORYZON presents final data on the Phase I trial with ORY-2001 at the Alzheimer's Association International Conference (AAIC-2017)

Mon, 24 Jul 2017 08:00:00 EDT

BARCELONA, SPAIN and CAMBRIDGE, MA--(Marketwired - July 24, 2017) -

  • Excellent safety data profile on 106 healthy volunteers
  • The molecule is brain penetrant
  • Data allows establishment of a safe administration scheme for long term efficacy studies

ProBility Media Corp. Further Expands International Educational and Training Product Offerings with Purchase of Cranbury International

Mon, 24 Jul 2017 07:57:46 EDT

HOUSTON, TX--(Marketwired - Jul 24, 2017) -  ProBility Media Corp. (OTCQB: PBYA), an EdTech company building the first full-service training and career advancement brand for the skilled trades, today announced that it has signed a binding letter of intent to purchase Cranbury International, an exporter of educational and reference materials, located in Montpelier, Vermont. The acquisition significantly expands ProBility's educational and training product offerings in South and Central America and the Caribbean. The closing is expected within 30 days.

Theratechnologies Annonce de Nouvelles Données concernant l'Antirétroviral sous Etude Ibalizumab et concernant EGRIFTAMD (tésamoréline injectable)

Mon, 24 Jul 2017 07:30:00 EDT

Résultats Présentés à la 9ème Conférence Scientifique de l'International AIDS Society (IAS 2017) à Paris, France

Theratechnologies Announces New Findings with the Investigational Antiretroviral Ibalizumab and with EGRIFTA® (tesamorelin for injection)

Mon, 24 Jul 2017 07:30:00 EDT

Results Presented at 9th IAS Conference on HIV Science (IAS 2017) in Paris, France

Genetic Technologies Receives Nasdaq Deficiency Notice

Fri, 21 Jul 2017 21:57:53 EDT

MELBOURNE, AUSTRALIA--(Marketwired - Jul 21, 2017) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), today announced that on 20 July 2017, it received a notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market, notifying the Company that its closing bid price has been below the minimum $US1.00 per share requirement for a period of 30 consecutive business days and that the Company has not met the minimum bid price requirement of $US1.00 per share for continued inclusion under Nasdaq Marketplace Listing Rules (the "Rules").

Hemostemix Announces Updates on Rights Offering and Private Placement

Fri, 21 Jul 2017 19:53:40 EDT

BLACKFALDS, ALBERTA--(Marketwired - July 21, 2017) -

eWellness Signs LOI For Comprehensive PT Services with US Health Center and another US Healthcare Payer Group

Fri, 21 Jul 2017 09:00:00 EDT

CULVER CITY, CA--(Marketwired - Jul 21, 2017) - eWellness Healthcare Corporation -- (OTCQB: EWLL) -- a provider of the state of the art PHZIO Platform for the physical therapy and telehealth markets, announced today that it has signed a Letter of Intent Agreement between US Health Center, Inc. ("USHC") and an undisclosed US healthcare provider. Between both USHC and the undisclosed US healthcare payer group they anticipate having approximately 100,000 healthcare insured customers by the end of 2017. The Parties to this LOI have agreed to use their best efforts to conclude Definitive Agreements between the Parties over the next 90 days. According to eWellness, these new agreements (if executed) are anticipated to generate initially up to $4.2 million in annual reoccurring gross revenue for the Company. This level of sales is anticipated to allow the Company to gain cash flow positive operations during the latter part of 2017.

ECPO Files Issuers Company Related Action Notification with the Financial Industry Regulatory Authority requesting Name and Symbol Change

Thu, 20 Jul 2017 13:19:52 EDT

The Company Also Updated Progress on the Validation Process for its ITV-1 Patented HIV/AIDS Treatment

NSAV to Spin-Off Hemp Beer Subsidiary to Shareholders

Thu, 20 Jul 2017 09:20:00 EDT

CRESCO, PA--(Marketwired - Jul 20, 2017) -  NSAV Holding, Inc. (OTC: NSAV), announced today that the Company will spin-off its hemp beer division as a stand-alone public company. In conjunction with the spin-off, NSAV shareholders will be awarded shares in the proposed public entity based upon their holdings in NSAV. The Company has already formed Hemp Beer Inc., a Colorado corporation, and has begun construction of its hemp beer website,

ContraFect Corporation Prices $40 Million Public Offering of Common Stock and Warrants

Thu, 20 Jul 2017 09:03:16 EDT

YONKERS, NY--(Marketwired - July 20, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the pricing of its underwritten public offering of 32,000,000 shares of its common stock and related warrants to purchase 16,000,000 shares of common stock with an exercise price of $1.55 per share at a combined public offering price of $1.25 per share and related warrant. All shares and warrants in the offering are to be sold by ContraFect. The gross proceeds from the offering will be $40.0 million.

SANUWAVE Appoints Alat Medika Indonesia as Distributor for dermaPACE and Liaison to Clinical Trials Participation for Company's Wound Care Product(s) in Indonesia

Thu, 20 Jul 2017 09:00:00 EDT

SUWANEE, GA--(Marketwired - Jul 20, 2017) - SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce that the Company has appointed Alat Medika Indonesia as distributor for dermaPACE® and liaison for clinical trials participation for Company's wound care product in Indonesia. The expected revenue from this agreement will be north of $1 million over the next three years.

Medical Marijuana Reports Record Month of Sales -- CFN Media

Thu, 20 Jul 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - Jul 20, 2017) -  CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article on Medical Marijuana Inc.'s (OTC PINK: MJNA) Kannaway® subsidiary and its record monthly sales in June.

CV Sciences, Inc. Cites Recent Clinical Study on Pharmaceutical-Grade CBD Shown to Lower Blood Pressure

Thu, 20 Jul 2017 08:45:00 EDT

Company Gaining Traction with Drug Candidate CVSI-007 to Become the Only FDA Approved Treatment for Smokeless Tobacco Addiction

Streetwise Reports Examines How Progress in Pain Control and Liver Disease Programs Spurs Rise in DURECT Corp.'s Rating

Thu, 20 Jul 2017 08:45:00 EDT

SAN FRANCISCO, CA--(Marketwired - July 20, 2017) - News about progress in two of this biotech's development programs prompted a rating upgrade by analyst Adam Walsh of Stifel Nicolaus & Company.

Propanc Biopharma Receives Acceptance of Key Patent Application for Cancer Treatment in China

Thu, 20 Jul 2017 08:30:00 EDT

Patent covers use of a pharmaceutical composition comprising trypsinogen and chymotrypsinogen

OncBioMune Acquires Propolis Product Line for German Partner

Thu, 20 Jul 2017 08:30:00 EDT

BATON ROUGE, LA--(Marketwired - July 20, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer vaccine technology and commercialization of a portfolio of products internationally, is pleased to announce the acquisition of the rights to six Aagaard® Propolis products for the Mexican markets from the Company's German partner roha Arzneimittel GmbH ("roha"). OncBioMune has begun the process to market the products across Mexico, with expectations for an official launch during the fourth quarter of 2017.

ANGLE plc: Preclinical Study Presented At Tumor Boston Summit

Thu, 20 Jul 2017 08:15:24 EDT

GUILDFORD, UNITED KINGDOM--(Marketwired - Jul 20, 2017) - ANGLE plc (AIM: AGL) (OTCQX: ANPCY)

National Research Council and Lexaria Bioscience Commence Laboratory Work

Thu, 20 Jul 2017 08:00:00 EDT

KELOWNA, BC--(Marketwired - July 20, 2017) - Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (CSE: LXX.CN) (CNSX: LXX) (the "Company" or "Lexaria") announces the start of laboratory work under its collaborative research program with the National Research Council of Canada ("NRC"), following the completion of preparation initiatives announced on March 14, 2017.

ORYZON to Regain Rights to ORY-1001 (RG6016)

Thu, 20 Jul 2017 07:16:55 EDT

Management to Host two Web Conferences today, July 20th

- at 10:00 am CET in Spanish and

- at 8:30 am ET in English

Clinical Teams From Top Pharma Companies Are Overcoming Challenges in Planning and Implementing Adaptive Trial Design Studies

Wed, 19 Jul 2017 19:23:00 EDT

RESEARCH TRIANGLE PARK, NC--(Marketwired - July 19, 2017) - A recent study of Top 10, Top 50, and small medical device companies found that addressing regulators' concerns for late-stage studies is the most common challenge clinical development teams encounter during their adaptive trial design preparations, according to research published by business intelligence firm Cutting Edge Information.

ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants

Wed, 19 Jul 2017 16:05:35 EDT

YONKERS, NY--(Marketwired - July 19, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that it has commenced an underwritten public offering of its common stock and warrants to purchase additional shares of its common stock. All of the securities in the offering are to be sold by ContraFect.

3D Signatures Inc. Announces Short Form Prospectus Offering to Raise Up to C$5 Million

Wed, 19 Jul 2017 12:34:54 EDT

TORONTO, ONTARIO--(Marketwired - July 19, 2017) -

The Alliance for Regenerative Medicine Announces Presenting Companies at 2017 Cell & Gene Meeting on the Mesa

Wed, 19 Jul 2017 10:16:21 EDT

WASHINGTON, DC--(Marketwired - Jul 19, 2017) - The Alliance for Regenerative Medicine (ARM) today announced the initial slate of companies selected to present at its upcoming Cell & Gene Meeting on the Mesa annual conference, October 4-6, 2017.

UPDATE - Medovex Corporation Announces First Human Cases Using Its DenerveX Device and First Revenue Events

Wed, 19 Jul 2017 09:17:59 EDT

Highly Disruptive and Patented Less Invasive Device with Faster Recovery Time than Current Surgical Treatment Options for Facet Joint Syndrome

Mobile Games Provide Inroads to Cannabis Consumers -- CFN Media

Wed, 19 Jul 2017 09:13:30 EDT

SEATTLE, WA--(Marketwired - Jul 19, 2017) -  CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article taking a closer look at fully-reporting First Harvest Corp. (OTCQB: HVST) and how mobile games could help cannabis companies reach consumers in an otherwise off-limits advertising environment.